ADAP News and Press, Adaptimmune Therapeutics plc From 03/11/22

ADAP, AVEO, BLDP, CORR, GOL, JAGX, LUNA, MTBC, PEI, PRTK For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Monday's open

This article focuses on the major influences towards a biotech company's share price, rather than their value or opportunity. These catalysts will be important to consider when timing your entry and exit points. This article will be the last that focuses on evaluating individual h...

PHILADELPHIA and OXFORDSHIRE, United Kingdom, March 08, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the fourth quarter and year ended December 31, 2021, before t...

I must say up front that I do not expect ADAP to make me a profit in the next 12 months because of the poor market conditions. However, I still like the science and am holding on to a small position for the longer term. ADAP has a BLA filing in 2022. For further details see:...

PHILADELPHIA and OXFORDSHIRE, United Kingdom, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announces the appointment of Cintia Piccina as Chief Commercial Officer effective January 31, 2022. “I a...

The potential for four or more interest rate hikes by the Federal Reserve over the course of 2022 has been weighing heavily on growth stocks of late. Yesterday, clinical and early commercial stage biopharmaceutical stocks took a particularly big hit in response to this risk factor. Investor...

Today, we revisit developmental concern Adaptimmune Therapeutics for the first time since spring of this year. The company appears to be making some progress advancing its pipeline and announced a significant collaboration deal with Genentech in September. A full investment analys...

Shares of the clinical-stage cell therapy company Adaptimmune Therapeutics (NASDAQ: ADAP) were down by 9.1% as of 2:37 p.m. ET on Wednesday. Earlier today, the biotech's shares were down by an unsightly 12.5% at their low point. Investors appear to be throwing in the towel o...

November has been brutal for biotech stocks. The SPDR S&P Biotech ETF has dropped by 5.1% just 2 1/2 weeks into the month. This bellwether biotech exchange-traded fund (ETF), in turn, has now declined by a hefty 12.7% so far this year. While no single culprit can be fingered as the ...

- Inhibition of AKT signaling during ex vivo T-cell expansion phase of manufacturing provides further proliferative potential and enhanced memory phenotype of next-gen SPEAR T-cells - - Data suggests that addition of AKT inhibitor (AKTi) during manufacture can remodel gene express...